Lisa G. Berdan

National Heart Lung and Blood Institute — United States

Medicine · Health Sciences

35h-index5.4kcitations65works20.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myocardial Infarction Research(35), Coronary Interventions and Diagnostics(23), Antiplatelet Therapy and Cardiovascular Diseases(19), Cardiac Imaging and Diagnostics(13), Venous Thromboembolism Diagnosis and Management(9)

Publications60 total

Lessons Learned from National Heart, Lung, and Blood Institute Covid-19 Clinical Trials
NEJM Evidence·2024· 1 citedOpen Access
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials
JAMA Network Open·2021· 10 citedOpen Access
The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study
Trials·2021· 23 citedOpen Access
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease
New England Journal of Medicine·2021· 286 citedOpen Access
Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial
JAMA Cardiology·2020· 81 cited
Facilitating translational team science: The project leader model
Journal of Clinical and Translational Science·2019· 16 citedOpen Access
Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness)
Medical Care·2018· 32 citedOpen Access
Good Clinical Practice Guidance and Pragmatic Clinical Trials
Circulation·2016· 120 citedOpen Access
The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations
American Heart Journal·2015· 16 cited
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
American Heart Journal·2014· 409 citedOpen Access
A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y <sub>12</sub> Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention
Circulation Cardiovascular Interventions·2012· 88 cited
The first call from Dad
American Heart Journal·2011
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Contemporary Clinical Trials·2011· 16 cited
Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non–ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY)
The American Journal of Cardiology·2009· 2 cited
Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes
New England Journal of Medicine·2009· 513 citedOpen Access
Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes
Circulation·2007· 54 citedOpen Access
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
American Heart Journal·2006· 94 cited
Abstract 2077: Shortening Time to Cardiac Catheterization Is Associated with Improved Outcomes Among Patients with Non-ST-segment Elevation Acute Coronary Syndromes: Results from the Randomized SYNERGY Trial
Circulation·2006
High-Risk Patients With Acute Coronary Syndromes Treated With Low-Molecular-Weight or Unfractionated Heparin
JAMA·2005· 64 cited
Characterization of Myocardial Infarction as an End Point in Two Large Trials of Acute Coronary Syndromes
The American Journal of Cardiology·2005· 3 cited
page 1 of 3Next →

Frequent Co-authors

Eric J. Topol(25), Robert A. Harrington(23), Robert M. Califf(20), Neal S. Kleiman(15), Kenneth W. Mahaffey(14), A. Michael Lincoff(11), David R. Holmes(8), Gordon Keeler(8), Matthew T. Roe(8), Maarten L. Simoons(8), Karen S. Pieper(7), Harvey D. White(6), Adrian F. Hernandez(6), Robert M. Califf(6), Christopher B. Granger(6), Paul W. Armstrong(5), Robert M. Califf(5), Shaun G. Goodman(5), Tyrus Rorick(5), James E. Tcheng(5)